Congressmen to regulators: BMS-Celgene merger will stifle competition and raise drug prices

15th January 2019 Uncategorised 0

U.S. Representatives Peter Welch and Francis Rooney are urging the Federal Trade Commission and Department of Justice to take a close look at Bristol-Myers’ $74 billion purchase of Celgene. Why? Past pharma mergers have spawned price hikes that hurt consumers, the congressmen say.

More: Congressmen to regulators: BMS-Celgene merger will stifle competition and raise drug prices
Source: fierce